A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia

OBJECTIVE: To evaluate the effectiveness of lurasidone as maintenance treatment for schizophrenia. METHOD: Adults experiencing an acute exacerbation of schizophrenia initially received 12–24 weeks of open-label treatment with lurasidone (40–80 mg/d, flexibly dosed). Patients who maintained clinical...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Psychopharmacol
Päätekijät: Tandon, Rajiv, Cucchiaro, Josephine, Phillips, Debra, Hernandez, David, Mao, Yongcai, Pikalov, Andrei, Loebel, Antony
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2016
Aiheet:
Original Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4717319/
https://ncbi.nlm.nih.gov/pubmed/26645209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0269881115620460
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia